Fulcrum Therapeutics to Participate in Upcoming September Conferences

Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [2] - The company will participate in investor meetings at the Wells Fargo Healthcare Conference on September 4, 2024, and the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 [1] Company Overview - Fulcrum Therapeutics specializes in small molecules aimed at improving the lives of patients with rare diseases that have high unmet medical needs [2] - The company's lead programs include losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD) [2] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene mis-expression [2]